Company profile: Cosciens Bio
1.1 - Company Overview
Company description
- Provider of biopharmaceutical diagnostic products, including Macimorelin, an orally active small molecule to diagnose adult growth hormone deficiency (AGHD), approved by the U.S. FDA and European Commission, and Macimorelin for childhood-onset growth hormone deficiency (CGHD) under development, leveraging its safety profile and clinical success in AGHD.
Products and services
- Diagnostic Products Development and Commercialization: Cosciens architects and commercializes biopharmaceutical diagnostic products for AGHD and CGHD indications, biopharmaceutical-class, advancing Macimorelin-based programs from clinical success to marketed diagnostics
- Macimorelin: Orally active small-molecule product for diagnosing adult growth hormone deficiency, U.S. FDA- and European Commission-approved, featuring oral administration and regulatory-cleared use in AGHD
- Macimorelin for CGHD: Under-development diagnostic for childhood-onset growth hormone deficiency, leveraging Macimorelin’s safety profile and AGHD clinical success to extend pediatric GH deficiency testing
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cosciens Bio
Alseres
HQ: United States
Website
- Description: Provider of diagnostic and therapeutic product development focused on disorders in the central.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alseres company profile →
Castle Creek Biosciences
HQ: United States
Website
- Description: Provider of personalized gene therapies for rare skin and connective tissue disorders, including D-Fi (dabocemagene autoficel) for dystrophic epidermolysis bullosa using autologous genetically modified fibroblasts to express type VII collagen; an autologous fibroblast technology platform; in-house cGMP commercial-scale manufacturing; and an expanded access policy for investigational products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Castle Creek Biosciences company profile →
DNage
HQ: The Netherlands
Website
- Description: Provider of life sciences research and development focused on discovering and developing products for aging diseases caused by DNA damage.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DNage company profile →
Larimar Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biotechnology treatments for complex rare diseases, including CTI-1601, a recombinant fusion protein designed to deliver human frataxin into mitochondria for patients with Friedreich’s ataxia (in Phase 1 clinical trials), and a proprietary protein replacement therapy platform intended to deliver missing proteins inside cells to treat rare diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Larimar Therapeutics company profile →
Processa Pharmaceuticals
HQ: United States
Website
- Description: Provider of drug product development to improve patient survival and quality of life, with a pipeline spanning oncology and GI: PCS6422 to improve chemotherapy safety/effectiveness in metastatic colorectal cancer; PCS11T for colorectal, small cell lung, and pancreatic cancers; PCS3117 for pancreatic cancer (FDA Orphan Designation); PCS499 for Ulcerative Necrobiosis Lipoidica; PCS12852 for gastroparesis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Processa Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cosciens Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cosciens Bio
2.2 - Growth funds investing in similar companies to Cosciens Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cosciens Bio
4.2 - Public trading comparable groups for Cosciens Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →